To the content
1 . 2020

Challenge in modern endocrinology: search for combined treatment on the back of insulin resistance (lecture)

AbstractInspite of the impressive progress in diabetes mellitus pharmacology and satisfactory control of glycemia, there is a lack of reduction a the risk of complications. In most cases, metformin monotherapy is not effective enough, and treatment should be started with complex therapy often even in the onset of the disease, affecting various components of pathogenesis. However, there are quite a few drugs in the endocrinologist's arsenal that act on insulin resistance and increase insulin sensitivity. As a modern pharmacotherapeutic approach to the treatment of type 2 diabetes, intended to increase insulin sensitivity, a novel antidiabetic drug Subetta can be considered in the complex therapy.

Keywords:diabetes mellitus, insulin resistance, metformin, antibodies, Subetta, complex therapy

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

For citation: Ametov A.S., Demidova T.Yu., Mkrtumyan A.M., Dudinskaya E.N., Sizova E.E. Challenge in modern endocrinology: search for combined treatment on the back of insulin resistance (lecture). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 60-9. doi: 10.33029/2304-9529-2020-9-1-60-69 (in Russian)



References

1. https://www.who.int/ru/news-room/fact-sheets/detail/diabetes

2. WHO. Scientific researches that were made with the aim to achieve global health service coverage. World Health Report 2013 ISBN: 978 92 4 156459 5

3. King P., Peacock I., Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999; 48 (5): 643-8. doi:10.1046/j.1365-2125.1999.00092.x

4. Zhang Y., Hu G., Yuan Z., Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012; 7 (8): e42551.

5. Dluhy R.G., McHanon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008; 358: 2630-3.

6. Dedov I.I., Mel'nichenko G.A., Fadeev V.F. Endocrinology. Moscow: GEOTAR-Media; 2007: 432 p. (in Russian)

7. Cefalu W. T. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood). 2001; 226 (1): 13-26. DOI: 10.1177/153537020122600103

8. De Meyts P. The insulin receptor and its signal transduction network. In: De Groot L.J., Chrousos G., Dungan K., Feingold K.R., Grossman A., Hershman J.M., et al. (eds.) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2017.

9. Sparrow L.G., Macaulay S.L. Insulin receptor complex and signaling by insulin. In: Bradshow R.A., Denis E.A. (eds). Hand Book of cell signaling. Academic Press, 2004; (1): 293-7.

10. Ametov A.S., Tertychnaya E.A. Insulin resistance and lipotoxicity-2 facets of one problem. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2019; 8 (2): 25-33. doi: 10.24411/2304-9529-2019-12003.(in Russian)

11. Taranushenko T.E., Oorzhak U.S., Salmina A.B., Kiseleva N.G., Panfilova V.N. Disorders of carbohydrate metabolism and insulin resistance in obesity in children. Poliklinika [Policlinic]. 2017; (Special Issue: Endocrinology): 37-45. (in Russian)

12. Gardner D.G., Shobeck D., eds. Greenspan’s basic and clinical endocrinology. 8th ed. New York: McGraw-Hill; 2007.

13. Surya M., Artham M.D., Lavie C.J. Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. Ochsner J. 2009; 9 (3): 124-32.

14. Wang Y., Rimm E.B., Stampfer M.J., et al. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005; 81 (3): 555-63.

15. Yusuf S., Hawken S., Ounpuu S., et al. INTERHEART Study investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366: 1640-9.

16. Hu G., Tuomilehto J., Silventoinen K., et al. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. Eur Heart J. 2004; 24: 2212-9.

17. Lofgren I., Herron K., Zern T., et al. Waist circumference is a better predictor than body mass index of coronary heart disease risk in overweight premenopausal women. J Nutr. 2004; 134: 1071-6.

18. Ametov A.S. Obesity. A modern view of pathogenesis and therapy. 2019; 1. Moscow: GEOTAR-Media, 382 p. (in Russian)

19. Diabetes mellitus: diagnosis, treatment, prevention. Edited by I.I Dedov, M.V. Shestakova. Moscow: Medical News Agency; 2011: 808 p. (in Russian)

20. Shestakova M.V., Breskina O. Yu. Insulin resistance: pathophysiology, clinical manifestations, treatment approaches. Consilium medicum. 2002; 4 (10): 523-7. (in Russian)

21. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med. 2009; 26 (12): 1185-92.

22. Ametov A.S. Type 2 diabetes mellitus. Problems and Solutions. Moscow: GEOTAR-Media; 2012: 704 p. (in Russian)

23. Cersosimo E., Triplitt C., Solis-Herrera C., et al. Pathogenesis of type 2 diabetes mellitus, 2018. [Electronic resource]. URL: https://www. ncbi.nlm.nih.gov/books/NBK279115/ (access date: 01.10.2019).

24. Drapkina O.M., Shifrina Yu.O. Molecular mechanisms of insulin resistance. Arterial’naya Gipertenziya [Arterial Hypertension]. 2010; 16 (5): 436-40. (in Russian)

25. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001; 108 (9): 1341-8.

26. Xiao C., Giacca A., Lewis G.F. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and p-cell dysfunction in humans. Diabetes. 2011; 60 (3): 918-24.

27. Ametov A.S., Prudnikova M.A. Prophylactic release metformin is a new standard un the treatment of type 2 diabetes. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2015; 1 (10): 19-26. (in Russian)

28. Viscoli C.M., Inzucchi S.E., Young L.H., et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017; 102 (3): 914-22. DOI: 10.1210/jc.2016-3237.

29. Instruction leaflet for medical use of the medicinal product Subetta. (Electronic resource). URL: https: //grls.rosminzdrav.ru/Grls_View_v2.aspx? RoutingGuid = b7a7b4b3-da1c-4c2d-9511-c1c319841ba8 & t = (access date 11.02.2020).

30. Gorbunov E.A., Nicoll J., Kachaeva E.V., Tarasov S.A., Ep-shtein O.I. Subetta increases phosphorylation of insulin receptor p-subinit alone and in the presence of insulin. Nutr Diabetes. 2015; 5 (7): е169. DOI: 10.1038nutd.2015.20

31. Nicoll J., Gorbunov E.A., Tarasov S.A. Epstein O. I. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Intern J Endocrinol. 2013; 2013: 925874. DOI: 10.155/2013/9 2 5 8 74.

32. Omilaenko N.V., Vorobev S.V., Nazheva M.I., Demidov I.A. The effectiveness of therapy based on the use of midget dozes of antibodies to C-end fragment beta-subunit of the receptor for insulin and antibodies to endothelial no- synthase in patients with non-alcoholic fatty liver disease with mellitus diabetes typ. Fundamental'nye issledovaniya [Fundamental Research]. 2015; (1-9): 1888-92. (in Russian)

33. Rogova N.V., Kulikova I.V., Statsenko V.I., Ryazanova A. Yu., Sergeeva S.A., Epshteyn O.I. Comparative efficacy of antibodies to C-terminal fragment of beta-subunit insulin receptor in patients with type 2 diabetes mellitus. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta [Journal of Volgograd State Medical University]. 2011; (1): 26-8. (in Russian)

34. Rogova N.V., Kulikova I.V., Statsenko V.I., Ostrovskaya V.I. Effect of antibodies to c-final fragment of p-subunit insulin receptor on the quality of life indicators in patients with type 2 diabetes. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta [Journal of Volgograd State Medical University]. 2011; (2): 46-8. (in Russian)

35. Vorob'yev S.V., Petrovskaya E.U., Kuz'menko N.A., Khripun I.A. А new drug in the complex therapy of diabetes mellitus. Post-registration experience in patients with type 1 and type 2 diabetes mellitus. Medit-sinskiy sovet [Medical Council]. 2018; (16): 29-34. (in Russian)

36. Mkrtumyan A., Romantsova T., Vorobiev S., Volkova A., Vorokho-bina N., Tarasov S., et al. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract. 2018; 142: 1-9.

37. A Randomized, multicenter, double-blind, parallel-group, placebo-controlled trial of efficacy and safety of Subetta in the combined treatment of patients with type II diabetes mellitus. Protocol MMH-SU-004-001 of 10/17/2017. Resolution of the Ministry of Healthcare of the Russian Federation No. 174 dated July 31, 2012 NCT01868646. (in Russian)

38. Mkrtumyan A.M. VITA Observation Program: Evaluation of the eectiveness and safety of the drug Subetta in the complex therapy of type 2 diabetes in ambulatory patients. Effektivnaya farmakoterapiya. Endokrinologiya [Effective Pharmacotherapy. Endocrinology]. 2020; 16 (2): 12-7. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»